$CVS

CVS Health (CVS) reported a $2B+ year-over-year increase in Aetna's adjusted operating income for H1 2026, driven by pricing, cost management, and operational improvements. The company raised its 2026 outlook by over $1B. McKesson (MCK) saw 33% revenue growth in Oncology & Multispecialty, while Align Technology (ALGN) expanded its Invisalign portfolio, with teen and growing-patient cases up 7.2% YoY.

CVS Health launched updated flu vaccines nationwide, aiming to boost pharmacy traffic and healthcare revenues. Analysts rate it 'Strong Buy' with a $114.25 price target, implying a 17.5% upside. Rival UnitedHealth Group has underperformed with 21.5% YTD and 30.2% 52-week gains.

CVS Health (NYSE:CVS) has gained 21% this year, with a 3% dividend and a 28 P/E ratio. Jim Cramer recommends holding the stock, citing strong leadership and Aetna's performance. Q2 revenue rose 7.3% to $106.1B, adjusted EPS increased to $2.58, and guidance was raised for 2026. Management expects continued momentum in Aetna's margin recovery but notes risks like Caremark membership decline and elevated medical costs.

CVS Health (CVS) shares rose 1% since its last earnings report, outperforming the S&P 500. Q2 2026 adjusted EPS was $2.58, up 42.5% YoY, beating estimates. Revenue increased 7.3% to $106.10B. All segments showed improved operating income, with Health Care Benefits leading the growth.

CVS Health's stock surged 38% over the past year, outperforming the S&P 500. However, its financial metrics like growth and profitability are mid-pack compared to peers. CVS's operating margin (3.4%) trails UnitedHealth (4.8%) and its valuation (25.5x earnings) is higher than peers. The market's enthusiasm is driven by Aetna's improvement, but management warned of membership declines in its PBM business. The company raised its 2026 EPS guidance to $7.90-$8.10 and expects 2027 EPS of at least $8.

CVS is opening smaller, pharmacy-only stores in underserved communities like Roxbury, focusing on prescription services due to retail challenges. The move follows store closures by CVS and Walgreens, driven by competition, theft concerns, and rising costs. Critics argue this creates inequity, while CVS aims to improve healthcare access. Walgreens has also tested smaller formats, and both chains face pressure from competitors like Amazon and dollar stores.

H-E-B ranked highest among brick-and-mortar pharmacies in JD Power's inaugural U.S. Pharmacy Digital Experience Study, scoring 724 out of 1,000. Publix and Costco followed with 713 and 709, respectively. The study highlights the importance of digital experience for pharmacy loyalty, with high satisfaction scores correlating with customer retention. Overall, brick-and-mortar pharmacies averaged 677, while mail order services averaged 707. Kaiser Permanente led the mail order segment with a score

CVS Health Corp (CVS) shares rose 3.9% to $97.60, with a 25.9% YTD gain. GF Value™ estimates the stock is 23.9% overvalued at $78.78. Insiders sold $323.7M in shares over the past year. CVS's P/E ratio is 25.8x, higher than its 5-year median of 17.4x, indicating a premium valuation. The GF Score™ is 76/100, with strengths in profitability and financial strength but average growth and valuation.

CVS Health (CVS) shares rose 3.7% Tuesday morning, driven by Jefferies analyst Brian Tanquilut's bullish commentary. He affirmed a buy rating with a $120 price target, citing management's EPS outlook of at least $8.44 for 2027, share buybacks, and Aetna's recovery. CVS has beaten earnings expectations for four straight quarters and raised its full-year guidance to $8.00 EPS.

Jefferies highlights CVS Health as a top healthcare services pick, citing strong Q2 earnings, a $120 price target, and factors like Aetna's recovery and buyback potential. CVS reported Q2 adjusted EPS of $2.58 on revenue of $106.1B, raising its full-year outlook. Moody's upgraded CVS's outlook to positive, noting progress in its health insurance business.